首页> 外文期刊>Knee surgery, sports traumatology, arthroscopy: official journal of the ESSKA >Mesenchymal stem cells for the treatment of cartilage lesions: From preclinical findings to clinical application in orthopaedics
【24h】

Mesenchymal stem cells for the treatment of cartilage lesions: From preclinical findings to clinical application in orthopaedics

机译:间充质干细胞用于治疗软骨损伤:从临床前发现到骨科临床应用

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: The aim of this systematic review is to examine the available clinical evidence in the literature to support mesenchymal stem cell (MSC) treatment strategies in orthopaedics for cartilage defect regeneration. Methods: The research was performed on the PubMed database considering the English literature from 2002 and using the following key words: cartilage, cartilage repair, mesenchymal stem cells, MSCs, bone marrow concentrate (BMC), bone marrow-derived mesenchymal stem cells, bone marrow stromal cells, adipose-derived mesenchymal stem cells, and synovial-derived mesenchymal stem cells. Results: The systematic research showed an increasing number of published studies on this topic over time and identified 72 preclinical papers and 18 clinical trials. Among the 18 clinical trials identified focusing on cartilage regeneration, none were randomized, five were comparative, six were case series, and seven were case reports; two concerned the use of adipose-derived MSCs, five the use of BMC, and 11 the use of bone marrow-derived MSCs, with preliminary interesting findings ranging from focal chondral defects to articular osteoarthritis degeneration. Conclusions: Despite the growing interest in this biological approach for cartilage regeneration, knowledge on this topic is still preliminary, as shown by the prevalence of preclinical studies and the presence of low-quality clinical studies. Many aspects have to be optimized, and randomized controlled trials are needed to support the potential of this biological treatment for cartilage repair and to evaluate advantages and disadvantages with respect to the available treatments. Level of evidence: IV.
机译:目的:本系统综述的目的是检查文献中可利用的临床证据,以支持骨科中的间充质干细胞(MSC)治疗策略来修复软骨缺损。方法:该研究是在PubMed数据库上进行的,其中参考了2002年的英语文献,并使用以下关键词:软骨,软骨修复,间充质干细胞,MSC,骨髓浓缩液(BMC),源自骨髓的间充质干细胞,骨骨髓基质细胞,脂肪来源的间充质干细胞和滑膜来源的间充质干细胞。结果:随着时间的流逝,系统的研究表明有关该主题的已发表的研究越来越多,并鉴定出72篇临床前论文和18项临床试验。在确定的针对软骨再生的18项临床试验中,没有一项是随机的,有5项是比较性的,有6项是病例系列,有7项是病例报告。其中两个涉及脂肪来源的MSC的使用,五个涉及BMC的使用,以及11骨髓来源的MSC的使用,其初步有趣的发现包括局灶性软骨缺损到关节性骨关节炎的变性。结论:尽管对这种用于软骨再生的生物学方法的兴趣日益浓厚,但有关该主题的知识仍是初步的,如临床前研究的普遍存在和低质量的临床研究所表明的。必须优化许多方面,并且需要随机对照试验来支持这种生物治疗软骨修复的潜力,并评估相对于可用治疗的优缺点。证据级别:IV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号